Corporate Updates

Biocon subsidiary acquires Pfizer’s research facility

Biocon

Our subsidiary has acquired a Chennai-based biological research facility from Pfizer Healthcare for an undisclosed amount, Biocon, a Biotechnology major announced recently.

dIgitalhealth

In a statement, the company said Biocon Biologics has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai.

“The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide,” Biocon Biologics CEO Christiane Hamacher said.

This investment will allow the company to fast-forward development of its biosimilars from lab to pilot scale, he added.

dIgitalhealth

The facility will house an early stage research and innovation centre, including a pilot scale R&D unit equipped with cell line development, drug product formulation laboratories and analytical R&D laboratories.

The facility is expected to be operational in a few months post qualification and will house over 250 scientists.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on


Most Popular

SUBSCRIBE OUR NEWSLETTER
200000+ Subscribers read it every day.
Subscribe Newsletter
To Top